Review article: biological agents in the treatment of Crohn's disease (original) (raw)
Biological agents in the treatment of Crohn's disease
Angelo Viscido
Alimentary Pharmacology and Therapeutics, 2002
View PDFchevron_right
Editorial: Cytokines and Intestinal Mucosal Immunity
Theresa Pizarro
Frontiers in Immunology, 2021
View PDFchevron_right
Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Brigitte Sola
Recent Patents on Inflammation & Allergy Drug Discovery, 2007
View PDFchevron_right
Tumour necrosis factor and inflammatory bowel disease
Keith Gardiner
British Journal of Surgery, 1997
View PDFchevron_right
AntiTumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohn's Disease
Christian D Muller
Recent Patents on Inflammation & Allergy Drug Discovery, 2007
View PDFchevron_right
Tumour necrosis factor in mouse models of chronic intestinal inflammation
Christoph Mueller
Immunology, 2002
View PDFchevron_right
Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease
Laura Reingold
American Journal of Physiology - Gastrointestinal and Liver Physiology, 2016
View PDFchevron_right
Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
Fabio Cominelli
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Crohn's disease: beyond antagonists of tumour necrosis factor
Jean-frédéric Colombel, Laurent Peyrin-biroulet
The Lancet, 2008
View PDFchevron_right
Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease
Sarah Thunberg
Clinical & Experimental Immunology, 2012
View PDFchevron_right
Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine
Anne Cooke
Clinical & …, 1990
View PDFchevron_right
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial
William Sandborn
Gastroenterology, 2001
View PDFchevron_right
Mucosal gene expression changes induced by anti‐TNF treatment in inflammatory bowel disease patients
Elena Milanesi
Drug Development Research
View PDFchevron_right
Review Article Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
Bruno de Mattos
Mediators of Inflammation
View PDFchevron_right
Anti-TNF Treatment in Inflammatory Bowel Disease
Hülya Hamzaoğlu
Annals of Gastroenterology, 2007
View PDFchevron_right
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety
William Sandborn
Inflammatory bowel diseases, 1999
View PDFchevron_right
New concepts in the pathophysiology of inflammatory bowel disease
Giorgos Bamias, S. De La Rue
Annals of internal medicine, 2005
View PDFchevron_right
TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis
Christoph Mueller
Journal of Experimental Medicine, 2010
View PDFchevron_right
Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo
Eleni Douni
European Journal of Immunology, 2002
View PDFchevron_right
Crohn's disease: future anti–tumor necrosis factor therapies beyond infliximab
Joshua Korzenik
Gastroenterology Clinics of North America, 2004
View PDFchevron_right
Intestinal-Specific TNFα Overexpression Induces Crohn’s-Like Ileitis in Mice
Giorgos Bamias
PLoS ONE, 2013
View PDFchevron_right
Systemic tumor necrosis factor-alpha production in experimental colitis
Philip Sherman
Digestive Diseases and Sciences, 1992
View PDFchevron_right
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Hermann Kessler
Gastroenterology, 2011
View PDFchevron_right
Tumour necrosis factor-alpha production stimulated by heat shock protein 70 and its inhibition in circulating dendritic cells and cells eluted from mucosal tissues in Crohn's disease
Miranda Lomer
Clinical and Experimental Immunology, 2006
View PDFchevron_right
Murine Monoclonal Anti-TNF Antibody Administration Has a Beneficial Effect on Inflammatory Bowel Disease That Develops in IL10 Knockout Mice
Stephen Malnick
Digestive Diseases and Sciences - DIGEST DIS SCI, 2002
View PDFchevron_right
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
Bruno de Mattos
Mediators of Inflammation, 2015
View PDFchevron_right
Role of cytokines in inflammatory bowel disease
fausto lopez
World Journal of Gastroenterology, 2008
View PDFchevron_right
Crohn’s Disease-Associated Mucosal Factors Regulate the Expression of TNF-like Cytokine 1A (TL1A) and its Receptors in Primary Subepithelial Intestinal Myofibroblasts and Intestinal Epithelial Cells
E. Filidou
Translational Research, 2017
View PDFchevron_right
Profile of soluble cytokine receptors in Crohn's disease
E. Quertinmont
Gut, 2005
View PDFchevron_right
Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis
Gert De Hertogh
Inflammatory Bowel Diseases, 2013
View PDFchevron_right
In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells
Erkki Savilahti
ISRN gastroenterology, 2012
View PDFchevron_right
10 Cytokines and inflammatory bowel disease
Dr. Anil Chandra Anand
Baillière's Clinical Gastroenterology, 1996
View PDFchevron_right
A critical approach to new forms of treatment of Crohn's disease and ulcerative colitis
Amado Salvador Peña
Alimentary Pharmacology & Therapeutics, 2002
View PDFchevron_right
TNF- neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis
Giorgos Bamias
Proceedings of the National Academy of Sciences, 2003
View PDFchevron_right
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
J. Ceuppens, K. Geboes
Alimentary Pharmacology and Therapeutics, 2001
View PDFchevron_right